Leading politicians, medical experts, and campaigners gathered at the Cannabis Europa 2025 conference in London to discuss ...

China-based MindRank’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved up to 10.5% weight loss in a ...

Neuron23 has dosed the first subject in the global Phase II NEULARK trial of NEU-411 for early Parkinson's disease (PD).

Teva Pharmaceutical has reported the final analysis of the PEARL Phase IV migraine prevention trial of Ajovy (fremanezumab).

The FDA's new genAI-assisted scientific review technology, named Elsa, was officially adopted by the agency on 2 June.

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational ...

The COMP005 study (NCT05624268) evaluated a placebo against COMP360, a synthetic, proprietary formulation of psilocybin, for ...

Vertex Pharmaceuticals has shared data from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, evaluating ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

Lundbeck’s Vyepti (eptinezumab) has met both the primary and secondary endpoints in the placebo-controlled Phase IV ...

Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of vaccine, TG4050.